Osteopontin expression in salivary gland cancer Kristine Bjørndal, Christian Godballe, Jørgen...
-
Upload
cedric-driver -
Category
Documents
-
view
214 -
download
1
Transcript of Osteopontin expression in salivary gland cancer Kristine Bjørndal, Christian Godballe, Jørgen...
Osteopontin expression in Osteopontin expression in salivary gland cancersalivary gland cancer
Kristine Bjørndal, Christian Godballe, Kristine Bjørndal, Christian Godballe, Jørgen Johansen, Jens Overgaard, Jørgen Johansen, Jens Overgaard,
Annelise KrogdahlAnnelise Krogdahl
Odense University Hospital, DKOdense University Hospital, DK
Aim of the studyAim of the study
ToTo evaluate osteopontin evaluate osteopontin expression and its prognostic expression and its prognostic information in salivary gland information in salivary gland
cancercancer
MaterialMaterial
• Salivary gland carcinomas treated at Odense Salivary gland carcinomas treated at Odense University HospitalUniversity Hospital
• 1990-20051990-2005• 48% males and 52% females48% males and 52% females• Clinical data retrieved from the national Clinical data retrieved from the national
database DASPYTCAdatabase DASPYTCA• Immunohistochemical investigations performed Immunohistochemical investigations performed
on surgical specimens on surgical specimens • Revision Revision
MaterialMaterial
199 patients199 patients3 – records 3 before 19903 – records 3 before 1990
5 metastases 10 - tumor5 metastases 10 - tumor
1 – follow-up 3 changed 1 – follow-up 3 changed diagnosisdiagnosis 174 patients174 patients (OPN + follow-up)(OPN + follow-up)
Number of coloured tumor cellsNumber of coloured tumor cells
• 0=none0=none• 1=<1/1001=<1/100• 2=1/100-1/10 2=1/100-1/10 • 3=1/10-1/33=1/10-1/3• 4=1/3-2/34=1/3-2/3• 5=>2/35=>2/3
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5
Coloured tumorcells
%All salivary gland carcinomas stain. In 87% over
2/3 of the tumor cells are coloured
NO CUT POINT
Colour intensityColour intensity
0
5
10
15
20
25
30
35
40
45
0 1 2 3
INTENSITY • 0=NONE0=NONE• 1=weak1=weak• 2=intermediate2=intermediate• 3=strong3=strong
%
Examples
Colour intensities Examiner 1
Examiner 2
1 2 3
1 33 6 0
2 14 54 11
3 0 12 45
Kappa beregning i Stata
• kap v1 v2, tab
• v2
• v1 1 2 3 Total•• 1 33 6 0 39 • 2 14 54 11 79 • 3 0 12 45 57 •• Total 47 72 56 175
• Expected• Agreement Agreement Kappa Std. Err. Z Prob>Z•• 75.43 34.98% 0.6221 0.0539 11.53 0.0000
Histological subtypesHistological subtypes IntensityIntensity
SubtypeSubtype11 22 33 TotalsTotals
Adenoid cystic Adenoid cystic
carcinomacarcinoma33 2323 2828 5454
MucoepidermoidMucoepidermoid
carcinomacarcinoma88 88 1515 3131
Acinic cellAcinic cell
carcinomacarcinoma77 1515 00 2222
Polymorph low Polymorph low grade adenoc.grade adenoc.
44 1212 55 2121
Adenocarcinoma Adenocarcinoma NOSNOS
44 44 22 1010
Squamous cellSquamous cell
carcinomacarcinoma33 44 00 77
Carcinoma ex. Carcinoma ex. pleomorphpleomorph
44 22 11 77
Overlevelsesanalyser
Follow-up tid: Tid fra diagnose (dato for den første gang patienten ses på en Øre-Næse-Hals afdeling i forbindelse med aktuelle cancerdiagnose) til censorering, som kunne være:
1. Død2. Sidste follow-up tjek (9. september 2008 Fpas)Hvis patienten var død, blev dødsårsag registreret som en
af to:1. Død af sin spytkirtelcancer eller af komplikationer til
behandling af samme2. Død af andre årsager
Datoer
• Før selve beregningerne påbegyndes regnes datoer i Excel om til Stata-datoer:
• generate double ddate=date(doedcen, "MDY", 2020)
• generate double start=date(datoafd, "MDY", 2020)
• generate fol=ddate-start
• generate folaar=fol/365.25
CS analyser
• stset folaar, failure(mors)
• stsum
• sts graph
• sts list
• sts graph, ci
• stsum, by(ostint)
• sts graph, by(ostint)
CS hele materialet0
.00
0.2
50
.50
0.7
51
.00
0 5 10 15 20analysis time
Kaplan-Meier survival estimate
CS hele mat. med CI
0.2
5.5
.75
1
0 5 10 15 20analysis time
95% CI Survivor function
Kaplan-Meier survival estimate
CS i.f.t. OPN-status0
.00
0.2
50
.50
0.7
51
.00
0 5 10 15 20analysis time
ostint = 1 ostint = 2ostint = 3
Kaplan-Meier survival estimates
DSS hele materialet0
.00
0.2
50
.50
0.7
51
.00
0 5 10 15 20analysis time
Kaplan-Meier survival estimate
DSS hele mat med CI
0.2
5.5
.75
1
0 5 10 15 20analysis time
95% CI Survivor function
Kaplan-Meier survival estimate
DSS i.f.t. opn-status0.
000.
250.
500.
751.
00
0 5 10 15 20analysis time
ostint = 1 ostint = 2ostint = 3
Kaplan-Meier survival estimates
Proportional hazards assumption
• xi: stcox i.ostint, tvc(ostint) texp(ln(_t))
• P=0,071
Cox-regression
• xi: stcox i.ostint
•• _t Haz. Ratio Std. Err. z P>z [95% Conf. Interval]•
• _Iostint_2 .6793372 .2538967 -1.03 0.301 .3265545 1.413237• _Iostint_3 .639291 .2613488 -1.09 0.274 .2868921 1.424553
•
ConclusionConclusion
• Salivary gland carcinomas express Salivary gland carcinomas express osteopontinosteopontin
• Level of osteopontin expression cannot be Level of osteopontin expression cannot be used as a diagnostic or prognostic markerused as a diagnostic or prognostic marker
• Osteopontin is a potential target for anti-Osteopontin is a potential target for anti-cancer therapycancer therapy